Cadrenal Therapeutics Announces FDA's Feedback At Type D Meeting For CAD-1005 Inhibitor To Treat Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback
A medicine company got helpful feedback from the FDA about their new drug for a rare blood condition. This is a positive sign that the company is on track, though the drug still needs more testing before people can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.